BioMarin (BMRN) | Financial Analysis & Statements
BioMarin Pharmaceutical Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
874.6M
Gross Profit
598.9M
68.47%
Operating Income
-44.6M
-5.10%
Net Income
-46.6M
-5.33%
EPS (Diluted)
$-0.24
Balance Sheet Metrics
Total Assets
7.6B
Total Liabilities
1.5B
Shareholders Equity
6.1B
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
-91.4M
Free Cash Flow
56.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
BioMarin Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 2.9B | 2.4B | 2.1B | 1.8B |
| Cost of Goods Sold | 717.4M | 580.2M | 514.9M | 483.7M | 470.5M |
| Gross Profit | 2.5B | 2.3B | 1.9B | 1.6B | 1.4B |
| Gross Margin % | 77.7% | 79.7% | 78.7% | 76.9% | 74.5% |
| Operating Expenses | |||||
| Research & Development | 921.9M | 747.2M | 746.8M | 649.6M | 628.8M |
| Selling, General & Administrative | 1.2B | 1.0B | 937.3M | 854.0M | 759.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.1B | 1.8B | 1.7B | 1.5B | 1.4B |
| Operating Income | 409.5M | 474.2M | 158.1M | 46.0M | -74.3M |
| Operating Margin % | 12.7% | 16.6% | 6.5% | 2.2% | -4.0% |
| Non-Operating Items | |||||
| Interest Income | 74.9M | 74.9M | 58.3M | 18.0M | 10.5M |
| Interest Expense | 10.9M | 12.3M | 16.7M | 15.4M | 14.7M |
| Other Non-Operating Income | 9.0M | 5.3M | -10.5M | 101.6M | 3.8M |
| Pre-tax Income | 482.5M | 541.8M | 188.6M | 149.6M | -75.4M |
| Income Tax | 133.6M | 114.9M | 20.9M | 8.0M | -11.3M |
| Effective Tax Rate % | 27.7% | 21.2% | 11.1% | 5.4% | 0.0% |
| Net Income | 348.9M | 426.9M | 167.6M | 141.6M | -64.1M |
| Net Margin % | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% |
| Key Metrics | |||||
| EBITDA | 572.9M | 640.5M | 309.7M | 163.3M | 55.4M |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Basic Shares Outstanding | 191787000 | 190027000 | 187834000 | 185266000 | 182852000 |
| Diluted Shares Outstanding | 191787000 | 190027000 | 187834000 | 185266000 | 182852000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
BioMarin Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.3B | 942.8M | 755.1M | 724.5M | 587.3M |
| Short-term Investments | 248.9M | 194.9M | 318.7M | 567.0M | 426.6M |
| Accounts Receivable | 908.2M | 660.5M | 633.7M | 461.3M | 373.4M |
| Inventory | 1.3B | 1.2B | 1.1B | 894.1M | 776.7M |
| Other Current Assets | 185.8M | 201.5M | 141.4M | 104.5M | 110.4M |
| Total Current Assets | 4.0B | 3.2B | 3.0B | 2.8B | 2.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 574.6M | 542.9M | 538.7M | 475.7M | 444.2M |
| Goodwill | 606.2M | 647.7M | 687.1M | 731.0M | 781.0M |
| Intangible Assets | 213.8M | 255.3M | 294.7M | 338.6M | 388.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.8B | 1.7B | 1.7B | 1.7B | 1.6B |
| Total Non-Current Assets | 3.6B | 3.8B | 3.9B | 3.6B | 3.7B |
| Total Assets | 7.6B | 7.0B | 6.8B | 6.4B | 6.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 312.8M | 235.4M | 315.5M | 231.2M | 199.7M |
| Short-term Debt | 8.7M | 7.6M | 502.7M | 10.4M | 10.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 31.0M | 13.1M | 33.9M | 28.5M | 54.5M |
| Total Current Liabilities | 759.0M | 607.0M | 1.2B | 588.9M | 546.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 597.2M | 595.1M | 593.1M | 1.1B | 1.1B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 150.8M | 128.8M | 119.9M | 100.0M | 113.5M |
| Total Non-Current Liabilities | 748.0M | 724.0M | 713.0M | 1.2B | 1.2B |
| Total Liabilities | 1.5B | 1.3B | 1.9B | 1.8B | 1.7B |
| Equity | |||||
| Common Stock | 192.0K | 191.0K | 189.0K | 186.0K | 184.0K |
| Retained Earnings | 154.2M | -194.7M | -621.6M | -789.2M | -930.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.1B | 5.7B | 5.0B | 4.6B | 4.3B |
| Key Metrics | |||||
| Total Debt | 605.9M | 602.7M | 1.1B | 1.1B | 1.1B |
| Working Capital | 3.2B | 2.6B | 1.8B | 2.2B | 1.7B |
Balance Sheet Composition
BioMarin Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 348.9M | 426.9M | 167.6M | 141.6M | -64.1M |
| Depreciation & Amortization | 79.6M | 96.4M | 104.4M | 102.0M | 108.0M |
| Stock-Based Compensation | 181.4M | 201.6M | 207.1M | 196.3M | 197.3M |
| Working Capital Changes | -293.7M | -216.4M | -336.5M | -96.4M | 66.0M |
| Operating Cash Flow | 584.1M | 588.0M | 101.4M | 295.1M | 301.2M |
| Investing Activities | |||||
| Capital Expenditures | -103.0M | -85.4M | -96.7M | -121.0M | -95.6M |
| Acquisitions | -285.2M | - | - | - | - |
| Investment Purchases | -355.9M | -410.2M | -868.5M | -611.8M | -937.1M |
| Investment Sales | 337.8M | 633.0M | 864.9M | 620.0M | 691.0M |
| Investing Cash Flow | -406.3M | 148.5M | -100.3M | -9.4M | -342.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | 0 | -495.0M | -2.3M | -2.6M | -3.0M |
| Financing Cash Flow | -56.9M | -575.7M | -88.1M | -88.0M | -49.2M |
| Free Cash Flow | 717.0M | 475.4M | 51.6M | 44.4M | 185.3M |
| Net Change in Cash | 121.0M | 160.8M | -87.0M | 197.7M | -90.7M |
Cash Flow Trend
BioMarin Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
30.34
Forward P/E
8.09
Price to Book
1.73
Price to Sales
3.26
PEG Ratio
-0.22
Profitability Ratios
Profit Margin
10.83%
Operating Margin
22.49%
Return on Equity
5.94%
Return on Assets
5.58%
Financial Health
Current Ratio
5.21
Debt to Equity
10.56
Beta
0.29
Per Share Data
EPS (TTM)
$1.80
Book Value per Share
$31.65
Revenue per Share
$16.80
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BMRN | 10.4B | 30.34 | 1.73 | 5.94% | 10.83% | 10.56 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
| Revolution Medicines | 28.6B | -22.73 | 16.24 | -58.07% | 0.00% | 26.19 |
Financial data is updated regularly. All figures are in the company's reporting currency.






